Momenta Phama (MNTA) Tops Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Momenta Pharmaceuticals (MNTA) PT Lowered to $26 at Stifel on 1Q Results; 'Patents & Production Issues Continue'
May 2, 2017 2:36 PM EDTStifel lowered its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $30.00) while maintaining a Buy rating, as the company reported first quarter earnings results.
Analyst Thomas Shrader notes the company reported first quarter results, as management improved cash position due to a one-time... More
